(2S)-2-[[(2S)-2-azaniumyl-4-methylpentanoyl]amino]-4-methylsulfanylbutanoate | 36077-39-1

• 物质功能分类: 生物化工 - 生化试剂 - 氨基酸
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (2S)-2-[[(2S)-2-azaniumyl-4-methylpentanoyl]amino]-4-methylsulfanylbutanoate
• CAS: 36077-39-1
• 化学式: C11H22N2O3S
• 分子量: 262.37
• InChiKey: NTISAKGPIGTIJJ-IUCAKERBSA-N

物化性质

• 沸点：
  493.8±45.0 °C(Predicted)
• 密度：
  1.143±0.06 g/cm3(Predicted)
• 溶解度：
  DMSO（少许）、甲醇（少许）、水（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  -1.9
• 重原子数：
  17
• 可旋转键数：
  8
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.818
• 拓扑面积：
  118
• 氢给体数：
  3
• 氢受体数：
  5

安全信息

• 海关编码：
  2930909090

文献信息

• Purine derivatives having pharmacological action
  申请人：Co Pharma Corporation S.r.l.

  公开号：US05110798A1

  公开（公告）日：1992-05-05

  Compounds of formula I ##STR1## wherein R.sub.1 is OH or NH.sub.2 and R.sub.2 is H or NH.sub.2, R is H or lower alkyl, A is an alkyl chain optionally interrupted by heteroatoms and B is an amino acid, a di- or tri-peptide, are useful in human therapy.

  式I的化合物 ##STR1## 其中R.sub.1为OH或NH.sub.2，R.sub.2为H或NH.sub.2，R为H或低碳基，A是由杂原子间断的烷基链，B是氨基酸，二肽或三肽，可用于人类治疗。
• MUTANT PROTEIN HAVING THE PEPTIDE-SYNTHESIZING ACTIVITY
  申请人：ABE Isao

  公开号：US20070292916A1

  公开（公告）日：2007-12-20

  The present invention aims at providing an excellent peptide-synthesizing protein and a method for efficiently producing a peptide. The peptide is synthesized by reacting an amine component and a carboxy component in the presence of at least one of proteins shown in the following (I) and (II). (I) The mutant protein having an amino acid sequence comprising one or more mutations from any of the mutations 1 to 68, and the mutations 239 to 290 and 324 to 377 in an amino acid sequence of SEQ ID NO:2. (II) The mutant protein having an amino acid sequence comprising one or more mutations from any of the mutations L1 to L335 and M1 to M642 in an amino acid sequence of SEQ ID NO:208

  本发明旨在提供一种优秀的肽合成蛋白质及高效生产肽的方法。在以下（I）和（II）所示的蛋白质的至少一种存在下，通过在胺组分和羧组分存在下反应合成肽。其中，（I）为突变蛋白质，其氨基酸序列包括来自于突变1至突变68、突变239至突变290和突变324至突变377的一个或多个突变；（II）为突变蛋白质，其氨基酸序列包括来自于L1至L335和M1至M642的一个或多个突变。
• Mutant protein having the peptide-synthesizing activity
  申请人：Abe Isao

  公开号：US20070190602A1

  公开（公告）日：2007-08-16

  The present invention aims at providing an excellent peptide-synthesizing protein and a method for efficiently producing a peptide. The peptide is synthesized by reacting an amine component and a carboxy component in the presence of at least one of proteins shown in the following (I) and (II). (I) The mutant protein having an amino acid sequence comprising one or more mutations from any of the mutations 1 to 68, and the mutations 239 to 290 and 324 to 377 in an amino acid sequence of SEQ ID NO:2. (II) The mutant protein having an amino acid sequence comprising one or more mutations from any of the mutations L1 to L335 and M1 to M642 in an amino acid sequence of SEQ ID NO:208

  本发明旨在提供一种优异的合成肽蛋白质及高效生产肽的方法。在以下(I)和(II)所示的蛋白质的存在下，通过反应胺组分和羧基组分来合成肽。(I)突变蛋白质的氨基酸序列包括来自突变1到68和突变239到290以及SEQ ID NO:2的氨基酸序列中的突变324到377中的一个或多个突变。(II)突变蛋白质的氨基酸序列包括来自突变L1到L335和M1到M642和SEQ ID NO:208的氨基酸序列中的一个或多个突变。
• MUTANT PROTEIN HAVING PEPTIDE-PRODUCTION ACTIVITY
  申请人：Ajinomoto Co., Inc.

  公开号：EP1829968A1

  公开（公告）日：2007-09-05

  The present invention aims at providing an excellent peptide-synthesizing protein and a method for efficiently producing a peptide. The peptide is synthesized by reacting an amine component and a carboxy component in the presence of at least one of proteins shown in the following (I) and (II). (I) The mutant protein having an amino acid sequence comprising one or more mutations from any of the mutations 1 to 68, and the mutations 239 to 290 and 324 to 377 in an amino acid sequence of SEQ ID NO:2. (II) The mutant protein having an amino acid sequence comprising one or more mutations from any of the mutations L1 to L335 and M1 to M642 in an amino acid sequence of SEQ ID NO:208

  本发明旨在提供一种优良的多肽合成蛋白和一种高效生产多肽的方法。该多肽是在至少一种如下(I)和(II)所示的蛋白质存在下，通过胺组分和羧基组分反应合成的。 (I)突变体蛋白质，其氨基酸序列包含 SEQ ID NO:2 的氨基酸序列中的突变 1 至 68、突变 239 至 290 和突变 324 至 377 中的一个或多个突变。 (II)突变体蛋白质，其氨基酸序列包含以下突变中的一个或多个突变 SEQ ID NO:208 的氨基酸序列中的 L1 至 L335 突变和 M1 至 M642 突变中的任一个或多个突变的突变体蛋白。
• PURINE DERIVATIVES HAVING PHARMACOLOGICAL ACTION
  申请人：CO PHARMA CORPORATION

  公开号：EP0346460A1

  公开（公告）日：1989-12-20